WHO International Standard for anti-SARS-CoV-2 immunoglobulin.

Kristiansen, Paul A; Page, Mark; Bernasconi, Valentina; Mattiuzzo, Giada; Dull, Peter; Makar, Karen; Plotkin, Stanley; Knezevic, Ivana

Kristiansen, Paul A; Page, Mark; Bernasconi, Valentina; Mattiuzzo, Giada; Dull, Peter; Makar, Karen; Plotkin, Stanley; Knezevic, Ivana.

Kristiansen PA; Coalition for Epidemic Preparedness Innovations, Oslo, Norway.
Page M; National Institute for Biological Standards and Control, Potters Bar, UK.
Bernasconi V; Coalition for Epidemic Preparedness Innovations, Oslo, Norway.
Mattiuzzo G; National Institute for Biological Standards and Control, Potters Bar, UK.
Dull P; Bill & Melinda Gates Foundation, Seattle, WA, USA.
Makar K; Bill & Melinda Gates Foundation, Seattle, WA, USA.
Plotkin S; University of Pennsylvania, Philadelphia, PA, USA.
Knezevic I; WHO, Geneva 1211, Switzerland. Electronic address: knezevici@who.int.

Lancet ; 397(10282): 1347-1348, 2021 04 10.

Article in English | MEDLINE | ID: covidwho-1492774

Subject(s)

Antibodies, Viral/blood; COVID-19 Vaccines/standards; Immunoglobulins/blood; SARS-CoV-2/immunology; Humans; Reference Standards; Sensitivity and Specificity; World Health Organization

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulins / COVID-19 Vaccines / SARS-CoV-2 / Antibodies, Viral Type of study: Diagnostic study Topics: Vaccines Limits: Humans Language: English Journal: Lancet Year: 2021 Document Type: Article Affiliation country: S0140-6736(21)00527-4

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google